One Pager as on December 31, 2022
Agile quality portfolio from India's Big 100 Companies* | |
Exposure to the more stable half of the market | |
High conviction bottom up stock picking with a focus on alpha generation | |
*In terms of Full Market Capitalisation. |
Data as on December 31, 2022
Sector | MMLPY | Nifty 100 Index TRI |
Financial Services | 34.28% | 34.56% |
Information Technology | 13.28% | 12.49% |
Fast Moving Consumer Goods | 9.58% | 8.94% |
Oil Gas & Consumable Fuels | 7.34% | 12.48% |
Automobile And Auto Components | 6.23% | 4.80% |
Data as on December 31, 2022
Security | % to Net Assets |
HDFC Bank Limited | 9.20% |
ICICI Bank Limited | 9.02% |
Reliance Industries Limited | 7.34% |
Infosys Limited | 7.13% |
State Bank of India | 4.89% |
Larsen & Toubro Limited | 4.13% |
Hindustan Unilever Limited | 3.11% |
Tata Consultancy Services Limited | 2.85% |
Maruti Suzuki India Limited | 2.74% |
Axis Bank Limited | 2.66% |
Top 10 Holdings | 53.09% |
Fresh Additions | Complete Exits |
Security | Security |
Life Insurance Corporation Of India | Bank of Baroda |
Tega Industries Limited | Eicher Motors Limited |
Note:
The companies/stock(s) referred above are only for the purpose of disclosure of significant
portfolio changes during the month and should not be construed as recommendation to buy/sell/
hold. The fund manager may or may not choose to hold these companies/stocks, from time to
time. Investors are requested to consult their financial, tax and other advisors before taking any
investment decision(s). Data as on December 31, 2022
Turnover Ratio (Last 1 year) | 1.02 |
Standard Deviation | 20.61% |
Beta1 | 0.89 |
Sharpe Ratio# | 0.42 |
Jenson's Alpha2 | -0.0704 |
#Risk-free rate assumed to be 6.60% (MIBOR as on 31-12-22) - www.mmda.org
1. Beta is calculated on the basis of average monthly rolling returns as of last day of the
month since inception till December 31, 2022 and annualized. 2. Calculated for the period
since inception till December 31, 2022. | Data Source: ICRA Analytics, Bloomberg | Data as on
December 31, 2022
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 15-Mar-2019.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of
Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Abhinav Khandelwal is managing this scheme since March 1, 2022.
Ms. Fatema Pacha is managing this scheme since December 21, 2020. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 15-Mar-2019.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business
day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate. $Dedicated Fund Manager for Overseas Investments.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. The performance details provided above are of Growth Option under Regular Plan Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Abhinav Khandelwal manages 6 schemes and
Ms. Fatema Pacha manages 9 schemes of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on December 30, 2022.
This product is suitable for investors who are seeking*:
• Long term capital appreciation;
• Investment predominantly in equity and equity related securities including derivatives of large cap companies.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.